This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Ironwood Gains; GTSI Rejects Hostile Offer

NEW YORK ( TheStreet) -- Shares of Ironwood Pharmaceuticals (IRWD - Get Report) took off in extended trades late Monday after the company and partner Forest Laboratories (FRX) reported positive top-line results for a clinical trial of a drug to treat patients suffering from irritable bowel syndrome with constipation.

Ironwood shares leapt 23% to $12 on volume of more than 72,000, according to Nasdaq.com following the news. The Cambridge, Mass.-based company completed its initial public offering in early February with the stock pricing at $11.25 per share.

In a statement, Ironwood and Forest said the positive top-line results relate to the safety and effectiveness of their investigational drug linaclotide in the first of two phase III clinical trials.

The companies said a second phase III trial of the drug for similar patients is ongoing with top-line results expected sometime in the fourth quarter.

In other news after the closing bell, video game maker THQ Inc. (THQI) lowered its financial outlook after moving back the release date of its Red Faction Armageddon title to May 2011. It said in June that it would release the game in March 2011.

THQ now sees revenue of between $800 million and $825 million for its fiscal 2011 ending in March 2011 with a non-GAAP loss of 10 to 20 cents a share. Its previous view was for breakeven results on the year on sales ranging from $845 million to $865 million.

The stock closed Monday at $3.73, up 7%, with volume of 1.6 million vs. its usual churn of around 1 million. So far in 2010, however, the shares have fallen 31% through Monday's close.

On August 9, the company reported its first-quarter results, coming in with a non-GAAP loss of $14.4 million, or 21 cents a share, that was narrower than Wall Street expectations for a loss of 24 cents a share. The stock sold off in the wake of the report, however, tumbling from around $4.50 just prior to a scrape a 52-week low of $3.33 on August 13.

Also, GTSI Corp. (GTSI) should be in focus again on Tuesday after the Herndon, Va.-based provider of technology products and services to government agencies said its board has rejected an unsolicited buyout proposal from Eyak Technology LLC.

GTSI shares surged 33% to $6.89 during Monday's session on news of the hostile bid from Eyak, which values GTSI shares at $7 each.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
THQI $0.31 0.00%
FRX $99.00 -0.77%
IRWD $14.60 -3.34%
AAPL $132.65 1.82%
FB $81.91 0.47%

Markets

DOW 18,037.97 -42.17 -0.23%
S&P 500 2,108.92 -8.77 -0.41%
NASDAQ 5,060.2460 -31.8390 -0.63%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs